Conference Nordic HPB - NOLCA, HELSINKI

18 – 19 September 2025

Thursday 18 September

08.30                Registration

09.00                Welcome

09.10 – 10.30   Session I: HPB – Robotics / Mini-invasive

There’s enough evidence to justify robotic Whipple, tba 15 mins

There’s not enough evidence to justify robotic Whipple, Dyre Kleve, Oslo 15 mins

Open versus laparoscopic versus robotic liver surgery – New thoughts from ROC’n’ROLL / ROBOCOP trials? Christian Sturesson, Stockholm 15min

Should we ablate them all? – How to approach colorectal liver metastases after COLLISION / New COMET, Åsmund Fretland, Oslo 15min

DISCUSSION - 20min

10.30 – 10.50      Coffee/Exhibition

10.50 – 12.30      Session II: EUS / advanced endoscopic techniques

What’s new for cystic tumours – Johanna Laukkarinen, Tampere – 15 min

In seek for tissue in pancreatic cancer and cholangiocarcinoma– Tandem lecture: Oncologist&Endoscopist 20min

Why novel oncological therapies require tissue instead of cytology? – Oncologist tba 10min

How to get enough tissue? Endoscopist tba 10 min

Management of HPB surgery complications using EUS and ERCP – tba min

Palliative endoscopic / EUS techniques – Lessons from a low-volume center – Lauri Pautola, Joensuu 15 min

Surgery for all now? How to interpret latest evidence on chronic pancreatitis (ESCAPE trial)? – tba 15min

DISCUSSION 20 min

12.30 – 13.30    Lunch/Exhibition

13.30 – 15:00    Session III: Maximally invasive HPB

When oncologists make surgery happen: Downstaging in pancreatic cancer and cholangiocarcinoma, Katriina Jalkanen, Helsinki 15min

Venous resections – When and what to use as a graft?  What to do with splenic vein? How to deal with early / late thrombosis/stenosis? Elena Rangelova, Gothenburg 15min

New frontiers in transplant oncology: Cholangiocarcinoma, Pål-Dag Line, Oslo, 20 min

Treatment of locally advanced pancreatic cancer, Flavio Rocha, Portland, USA 30 min

DISCUSSION 10 mins

15.00 – 15.30      Poster presentations - Physical presence of the presenter mandatory at this time!

15.30 – 15.50      Coffee/Exhibition

15.50 – 16:40      Free papers

                    6-8 mins per presentation = 5-7 presentations.

16.40 – 17.00      Most important HPB papers 2024 - 2025 – Kjetil Søreide, Stavanger

17.00 – 17.30      New / ongoing / breaking results - trial / study session 1 (10 minutes each)

Nordic Pancreatic Cancer Network info – Roland Andersson, Lund

Transpapillary stent as a treatment option for B-C pancreatic fistulas after distal pancreatectomy – TRAMSPO trial, Asif Halimi, Umeå

                 Tromboprophylaxis in patients with risk of developing moderate or severe acute pancreatitis – TROPICAL trial – Suvi Sippola, Helsinki

17:30 – 17:40      Presidential address

17.40 – 18.00      General Assembly

19.15                Conference Dinner

Friday 19 September

NOLCA Chair: Per Stål and Malin Sternby Eilard

08.30 – 08.35      Welcome by Pia Österlund, Helsinki

HCC Real-world evidence” in the Nordics. Chair: Peter Jepsen

08.35 – 08.45      Introduction to the session including results of the PERLA study (prognosis of HCC treated with resection or ablation), Peter Jepsen, Aarhus

08.45 - 08.55      Treatment patterns and outcomes of patients with HCC in Denmark, Hans-Christian Pommergaard, Copenhagen

08.55 - 09.05      Treatment patterns and outcomes of patients with HCC in Finland, Pia Österlund, Helsinki

09.05 – 09.15      Treatment patterns and outcomes of patients with HCC in Sweden (OPAL study), Hannes Hagström, Stockholm

09.15 – 09.40     Roundtable: Peter Jepsen hosting, presenters seated on-stage, audience participating.

What is the role of RWE studies?

Why are these studies done separately for each country and not as Nordic collaborations? Discuss challenges.

09.40 – 10.05      Coffee/exhibition

10.05 - 10.20      Macrovascular invasion of HCC: What is it, and how does it affect locoregional and systemic treatments? Malin Sternby Eilard , Göteborg and Per Stål, Stockholm

10.20 - 10.45      Sequential treatments for HCC: SIRT → ICI → resection? Including a suggestion for a Nordic protocol, Bård Røsok, Oslo and tba

10.45 - 11.10      Invited star lecture on cholangiocarcinoma, tba

11.10 - 11.20      Young presenter #1, Abstract competition

11.20 - 11.30      Young presenter #2, Abstract competition

11.30 - 11.45      General Assembly NOLCA, Pia Österlund, Helsinki

11.45 - 12.45      Lunch and exhibition

12.45 - 13.15      New study / trial session 2 (10 minutes each)

Early diagnosis of hereditary pancreatic cancer (SHIELD study) – Anna Brodén, Lund

DISPAIR study group collaborative, Akseli Bonsdorff, Helsinki

Results from ASAC trail,  Sheraz Yaqub, Oslo

13.15 – 14.45      Session IV: HPB complications

How to assess risk of posthepatectomy liver failure preoperatively and where to set the treshold for resection? Stefan Gilg, Stockholm 15min

Reducing risks of bleeding & tromboembolic complications in HPB – What new does POISE3, HELIX, PRICE-2, and PREPOSTEROUS bring to the table? Ville Sallinen, Helsinki 15min

Bilobar colorectal liver metastasis – What is the optimal strategy? Double vein embolization, ALPPS, portal vein embolization, or two-stage hepatectomy? TBA 15min

Arterial resections in pancreatic surgery – When is the right time? How to deal with early/late thrombosis/stenosis/bleeding? TBA 20 min

Discussion 10 min

14.45                Prizes for best oral & poster abstract presentation

14.55 - 15.00      Summing up, Roland Andersson and Ville Sallinen